Analgesic effects of melatonin on post-herpetic neuralgia.

Objective: This study aims to explore the analgesic effects of melatonin on post-herpetic neuralgia and its possible mechanism.

Methods: A total of 48 PHN Wistar rats were divided into 4 groups randomly: Normal, PHN, PHN+MT and naloxone, 4P-PDOT or L-arginine+120 mg/kg MT (C). Heat pain latency was determined after MT injection for 20 min, 40 min, 80 min and 120 min respectively.

[Protective effects of Ginkgo biloba extract on the lung injury of dogs undergoing hypothermic cardiopulmonary bypass].

Objective: To study the protective effects of Ginkgo biloba extract (EGb) on the lung injury of dogs undergoing hypothermic cardiopulmonary bypass (CPB).

Methods: Fourteen healthy hybrid dogs were randomly divided into the control group and the EGb group, 7 in each group. EGb (8 mg/kg) was intravenously dripped to dogs in the EGb group before thoracotomy after anesthesia, while equal volume of normal saline was intravenously dripped to those in the control group.

[Erythrocyte protective effects of ginaton in patients undergoing hypothermic cardiopulmonary bypass].

Objective: To investigate the erythrocyte protective effects of Ginaton, a ginkgo biloba extract, in patients undergoing hypothermic cardiopulmonary bypass (CPB).

Methods: Sixty patients, who suffered from rheumatic heart disease of ASA grade II-III and scheduled for mitral valve replacement with intravenous anesthesia, were randomly assigned to two groups equally, the Ginaton group and the control group. They were administered with Ginaton 1 mg/kg and saline respectively via intravenous dripping before open heart surgery before beginning CPB.

[Effect of ginkgo biloba extract on plasma vascular endothelial growth factor during peri-operative period of cardiac surgery].

Objective: To investigate the effect and clinical value of ginkgo biloba extract (Ginaton) on the plasma vascular endothelial growth factor (VEGF) in patients during peri-operative period of cardiac surgery.

Methods: Twenty patients scheduled to receive cardiac operation were randomly assigned to 2 groups by a digital table. For the 10 patients in the control group, the cardiopulmonary bypass (CPB) was established in routine and received cold (4 degrees C) St.

[Effects of Ginkgo biloba extract (ginaton) on mRNA expression of bcl-2 and bcl-xL in myocardium of patients underwent hypothermic cardiopulmonary bypass].

Objective: To investigate the effects of Ginkgo biloba extract (Ginaton) on bcl-2 and bcl-xL mRNA expression in the myocardium of patients underwent hypothermic cardiopulmonary bypass (CPB).

Methods: Thirty congenital heart disease patients were randomly assigned to 2 groups, the control group and the treated group. Patients in both groups received St.

[Brain protective effects of ginkgo biloba leaf extract (ginaton) in patients undergoing hypothermic cardiopulmonary bypass].

Objective: To investigate the brain protective effects of Ginkgo biloba leaf extract (Ginaton) in patients who underwent hypothermic cardiopulmonary bypass (CPB).

Methods: Sixty patients with rheumatic heart disease of ASA grade II-III, who were scheduled for mitral valve replacement with intravenous anaesthesia, were randomly assigned to two groups, the Ginaton group (30 patients) treated with Ginaton 1 mg/kg by intravenous dripping before open heart for CPB, and the control group (30 patients) with normal saline instead. Blood was synchronously collected from arteriae radialis and vena jugularis interna at 5 time points, namely, before CPB (T1), nasopharyngeal temperature (lowered to 30-31 degrees C) stabilized stage (T2), nasopharyngeal temperature restoration (36 degrees C) stage (T3), 30 min after CPB (T4) and 3 after CPB (Ts) for determining blood gas, lactate acid concentration, activity of superoxide dismutase (SOD) and malonaldehyde (MDA) content.

[Effects of Ginaton on the markers of myocardial injury during cardiopulmonary bypass].

Objective: To evaluate the effects of Ginaton (Ginkgo biloba leaf extract) on the myocardial injury markers (MIMs) during cardiopulmonary bypass (CPB).

Methods: Forty patients with congenital heart diseases, scheduled to take atrial septum or ventricular septum repairing operation, were randomly divided into the Ginaton group and the control group, 20 cases in each group. Patients in both groups received St.

Esmolol protects the myocardium and facilitates direct version intracardiac operation with a beating heart.

In recent years there has been renewed interest in beating heart surgery using the ultra-active and selective beta1-blocker, esmolol. However, there has not been a report of its use in direct version intracardiac surgery with beating heart. Twenty-four patients undergoing elective direct version intracardiac surgery (mitral valve replacement) were divided randomly into 2 groups: control group (normothermia cardiopulmonary bypass (CPB) direct version intracardiac beating heart surgery) and esmolol group (normothermia CPB direct version intracardiac beating heart surgery and intravenous esmolol drip during CPB to maintain heart rate at 30-50 beats/min).